Janssen U.S. Transparency Report
Our third annual Janssen U.S. Transparency Report reflects our commitment to responsible business practices that put patients first, including how we invest our resources, price our medicines, and help people who need our medicines get access to them.Open Video
“We believe enhancing transparency is a positive step toward a more sustainable, results-based health system that delivers greater access to care at a more manageable cost. As our third annual U.S. Transparency Report shows, the average net price of our medicines in the U.S. has decreased for two years in a row, and we have maintained our significant investment in discovering and developing transformational medicines for patients facing some of the world’s most challenging diseases. This year, our report also details our plan to include list price and typical patient out-of-pocket costs in our U.S. pharmaceutical TV advertising.”
Scott White Company Group Chairman North America Pharmaceuticals
5 Things to Know about our 2018 U.S. Transparency Report
For the second year in a row, the average net price of our medicines decreased.
In 2018, our average net price declined 6.8%. This is because the approximately $21 billion in discounts and rebates we provided to payers and providers outweighed our single-digit list price increase.
Our investment in research and development is 86 percent more than what we spent on marketing and sales.
In 2018, we invested $8.4 billion in global R&D. And we have more than 100 potential new medicines in development.
We’ve developed a common-sense way to make clearer for patients what they may pay for our medicines.
Starting with our most frequently prescribed medicine, we’re voluntarily including list price and typical out-of-pocket costs in our U.S. pharmaceutical TV advertising, with additional information available on our DTC Disclosures page.
We helped approximately 1 million patients with access, affordability, and treatment support through the Janssen CarePath program.
This includes approximately 550,000 commercially insured patients who reduced their out-of-pocket costs through the Janssen CarePath Savings Program.
We worked with stakeholders to advance our ideas for a better healthcare system.
We’ve forged value-based contracts with payers, participated in partnerships to explore value-based care models, and proposed practical policy solutions to bring down costs for patients.